Side-by-side · Research reference
EpitalonvsMK-677
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticDraft8/37 cited
BPhase 2Reviewed13/45 cited
Epitalon
Pineal bioregulator · Telomerase activator
SQ or IM · Abdomen · Daily for 10–20 days
MK-677
Oral GHS · Ibutamoren
Oral capsule · 1×/day
01Mechanism of Action
Parameter
Epitalon
MK-677
Primary target
Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003
Ghrelin receptor (GHS-R1a)Murphy 1998
Pathway
Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003
GHS-R1a → Gαq → Ca²⁺ → sustained GH pulses across 24 hrNass 2008
Downstream effect
Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003
Sustained GH + IGF-1 elevation; appetite stimulation; lean mass preservationNass 2008
Origin
Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003
Non-peptide spiroindane-piperidine small molecule designed at MerckMurphy 1998
Antibody development
—
—
02Dosage Protocols
Parameter
Epitalon
MK-677
Standard dose
5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003
Anecdotal community protocol. Russian clinical literature uses similar cycling.
10–25 mg / day oralNass 2008
25 mg used in Nass 2008 elderly trial; 10–15 mg common community dose.
Frequency
Once daily during a cycle
Once daily, oral
Lower / starter dose
2.5 mg / day
5 mg / day
Evidence basis
In-vitro telomerase + Russian clinical trialsKhavinson 2003
Phase 2 trials (Nass 2008, Murphy 1998)Nass 2008Murphy 1998
Duration
10–20 day cycles, 1–2× per year
8–16 weeks per cycle (off-cycle to reset receptor sensitivity)
Reconstitution
Bacteriostatic water
Oral, no reconstitution
Timing
Pre-sleep preferred (pineal alignment)
Pre-sleep preferred for natural GH pulse alignment
04Side Effects & Safety
Parameter
Epitalon
MK-677
Injection site reaction
Mild irritation
—
Sleep architecture
Improved subjective sleep quality (anecdotal)
—
Cancer risk
Theoretical via telomerase activation in pre-malignant cells
Contraindicated in active malignancy (GH/IGF-1 axis)
Long-term safety
Limited Western RCT data
—
Pregnancy / OB
Avoid
Avoid
Antibody formation
Not reported
—
Increased appetite
—
Strong appetite increase via ghrelin agonism
Water retention
—
Mild edema, paresthesias
Cardiovascular
—
No clear adverse signal in trials; congestive heart failure caution
Drowsiness
—
Common, especially during initial weeks
Absolute Contraindications
Epitalon
- ·Pregnancy / breastfeeding
- ·Active malignancy or pre-malignant state
MK-677
- ·Active malignancy
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
- ·Congestive heart failure (caution)
Relative Contraindications
Epitalon
- ·Family history of cancer
MK-677
- ·Untreated diabetes
- ·Pre-diabetes
- ·Severe insulin resistance
05Administration Protocol
Parameter
Epitalon
MK-677
1. Reconstitution
Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.
Capsule or oral solution. No injection.
2. Injection site
SQ — abdomen preferred. Rotate sites.
Oral. Take with or without food.
3. Timing
Pre-sleep preferred to align with pineal axis.
Pre-sleep preferred — aligns with natural GH pulse.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Capsule: room temp ≤25 °C, dry place.
5. Needle
29–31G, 4–8 mm insulin syringe.
Monitor HbA1c every 8–12 weeks during chronic use.